Interleukin-27 directly induces differentiation in hematopoietic stem cells

Laboratory of Stem Cell Therapy, Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Blood (Impact Factor: 10.45). 03/2008; 111(4):1903-12. DOI: 10.1182/blood-2007-06-093328
Source: PubMed


Interleukin (IL)-27, one of the most recently discovered IL-6 family cytokines, activates both the signal transducer and activator of transcription (STAT)1 and STAT3, and plays multiple roles in pro- and anti-inflammatory immune responses. IL-27 acts on various types of cells including T, B, and macrophage through the common signal-transducing receptor gp130 and its specific receptor WSX-1, but the effect of IL-27 on hematopoietic stem cells (HSCs) remains unknown. Here, we show that IL-27 together with stem cell factor (SCF) directly acts on HSCs and supports their early differentiation in vitro and in vivo. CD34(-/low)c-Kit(+)Sca-1(+)lineage marker(-) (CD34(-)KSL) cells, a population highly enriched in mouse HSCs, were found to express both IL-27 receptor subunits. In vitro cultures of CD34(-)KSL cells with IL-27 and SCF resulted in an expansion of progenitors including short-term repopulating cells, while some of their long-term repopulating activity also was maintained. To examine its in vivo effect, transgenic mice expressing IL-27 were generated. These mice exhibited enhanced myelopoiesis and impaired B lymphopoiesis in the bone marrow with extramedullary hematopoiesis in the spleen. Moreover, IL-27 similarly acted on human CD34(+) cells. These results suggest that IL-27 is one of the limited cytokines that play a role in HSC regulation.

Download full-text


Available from: Nobukazu Watanabe,
  • Source
    • "The resorbed material is transcytosed through the osteoclast [53] [54]. Mouse hematopoietic stem cells (HSCs) express both IL-27R subunits, gp130 and WSX-1[55]. Expression of mRNA IL-27 receptor subunits WSX-1 and gp130 was induced by MCSF in mouse bone marrow macrophages (osteoclast precursors) and direct engagement of IL-27R by IL-27 negatively regulated osteoclastogenesis [56]. In the same study Kamiya and colleagues showed that expression of IL-27 and IL-23 receptor subunits were also expressed in primary osteoblasts. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although the causes of inflammatory arthritis elude us, aberrant cytokine expression has been linked to joint pathology. Consequently, several approaches in the clinic and/or in clinical trials are targeting cytokines, e.g. tumor necrosis factor (TNF), Interleukin 23 (IL-23) and Interleukin 17 (IL-17), with the goal of antagonizing their respective biologic activity through therapeutic neutralizing antibodies. Such, cytokine signaling-dependent molecular networks orchestrate synovial inflammation on multiple levels including differentiation of myeloid cells to osteoclasts, the central cellular players in arthritis-associated pathologic bone resorption. Hence, understanding of the cellular and molecular mechanisms elicited by synovial cytokine networks that dictate recruitment, differentiation and activation of osteoclast precursors and osteoclasts, respectively, is central to shaping novel therapeutic options for inflammatory arthritis patients. In this article we are discussing the complex signaling interactions involved in the regulation of inflammatory arthritis and it's associated bone loss with a focus on Interleukin 27 (IL-27). The present review will discuss the primary bone-degrading cell, the osteoclast, and on how IL-27, directly or indirectly, modulates osteoclast activity in autoimmune-driven inflammatory joint diseases.
    Cytokine & growth factor reviews 11/2012; 24(2). DOI:10.1016/j.cytogfr.2012.10.001 · 5.36 Impact Factor
  • Source
    • "Experimental evidence indicates that STAT3 plays a very crucial role in hematopoiesis, in mediating immune response and in regulation of differentiation, proliferation, angiogenesis, metastasis, and apoptosis through its modulation of STAT3 target genes (Seita et al., 2008; Hankey, 2009). Inhibition of STAT3 activity by either STAT3 knock-out or through inhibition of STAT3 function, blocked v-Src-induced transformation, indicating the important role of STAT3 in malignant transformation (Bromberg et al., 1998; Turkson et al., 1998). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic myeloid leukemia (CML) is initially driven by the bcr-abl fusion oncoprotein. The identification of bcr-abl led to the discovery and rapid translation into the clinic of bcr-abl kinase inhibitors. Although, bcr-abl inhibitors are efficacious, experimental evidence indicates that targeting bcr-abl is not sufficient for elimination of minimal residual disease found within the bone marrow (BM). Experimental evidence indicates that the failure to eliminate the leukemic stem cell contributes to persistent minimal residual disease. Thus curative strategies will likely need to focus on strategies where bcr-abl inhibitors are given in combination with agents that specifically target the leukemic stem cell or the leukemic stem cell niche. One potential target to be exploited is the Janus kinase (JAK)/signal transducers and activators of transcription 3 (STAT3) pathway. Recently using STAT3 conditional knock-out mice it was shown that STAT3 is critical for initiating the disease. Interestingly, in the absence of treatment, STAT3 was not shown to be required for maintenance of the disease, suggesting that STAT3 is required only in the tumor initiating stem cell population (Hoelbl et al., 2010). In the context of the BM microenvironment, STAT3 is activated in a bcr-abl independent manner by the cytokine milieu. Activation of JAK/STAT3 was shown to contribute to cell survival even in the event of complete inhibition of bcr-abl activity within the BM compartment. Taken together, these studies suggest that JAK/STAT3 is an attractive therapeutic target for developing strategies for targeting the JAK-STAT3 pathway in combination with bcr-abl kinase inhibitors and may represent a viable strategy for eliminating or reducing minimal residual disease located in the BM in CML.
    Frontiers in Oncology 04/2012; 2:30. DOI:10.3389/fonc.2012.00030
  • Source
    • "The signal transducer and activator, STAT3 regulates the expression of target genes involved in cell-cycle progression and apoptosis, and promotes cellular transformation as well as abnormal cell proliferation10,11. The deregulation and constitutive activation of STAT3 are frequently observed in a large number of primary tumors and cancer-derived cells including hematologic malignancies, breast cancer, prostate cancer, and HCC 12. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The PI3K/Akt/mTOR and JAK/STAT3 signaling pathways are important for regulating apoptosis, and are frequently activated in cancers. In this study, we targeted STAT3 and mTOR in human hepatocellular carcinoma Bel-7402 cells and examined the subsequent alterations in cellular apoptosis. The expression of STAT3 was silenced with small interfering RNA (siRNA)-expressing plasmid. The activity of mTOR was inhibited using rapamycin. Following treatment, Annexin V/propidium iodide staining followed by flow cytometry and Hoechst33258 immunofluorescence staining was used to examine cellular apoptosis. JC-1 staining was used to monitor depolarization of mitochondrial membrane (ΔΨm). Furthermore, the expression of activated caspase 3 protein was analyzed by Western blotting. Compared to non-treated or control siRNA-transfected cells, significantly higher levels of apoptosis were detected in siSTAT3-transfected or rapamycin-treated cells (P < 0.05), which was further enhanced in cells targeted for both molecules (P < 0.05). The pro-apoptotic effects were accompanied with concomitant depolarization of mitochondrial membrane and up-regulation of activated caspase 3. Combined treatments using rapamycin and STAT3 gene silencing significantly increases apoptosis in Bel-7402 cells, displaying more dramatic effect than any single treatment. This study provides evidence for targeting multiple molecules in cancer therapy.
    International journal of medical sciences 03/2012; 9(3):216-24. DOI:10.7150/ijms.4004 · 2.00 Impact Factor
Show more